Pricing Log in Create free account

Regencell Bioscience Holdings Limited (RGC) vs Xeris Biopharma Holdings, Inc. (XERS)

Regencell Bioscience Holdings Limited and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Regencell Bioscience Holdings Limited and Xeris Biopharma Holdings, Inc. are of similar size ($2.6B and $2.4B). Regencell Bioscience Holdings Limited has the higher net margin (0.00% vs −1.76%) and the lower return on invested capital (0.00% vs 27.2%). Across the 12 metrics below, Regencell Bioscience Holdings Limited leads on 7 and Xeris Biopharma Holdings, Inc. on 5.

Valuation

Metric RGC XERS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S — 6.36 2.08
P/B n/m 48.03 1.79
Price to free cash flow n/m 32.23 16.29
EV/EBITDA 1.13 46.61 12.22
EV/Sales n/m 6.70 2.87
Earnings yield (19.96%) (0.31%) (15.94%)
Free cash flow yield 0.00% 3.10% 0.00%

Profitability

Metric RGC XERS Drug Manufacturers Specialty & Generic median
Gross margin — 87.38% 53.51%
Operating margin — 12.70% 0.00%
Net margin 0.00% (1.76%) (2.45%)
Free cash flow margin 0.00% 20.00% 0.00%
Return on equity 0.00% (27.11%) (0.80%)
Return on assets 0.00% (1.64%) (1.67%)
Return on invested capital 0.00% 27.22% 0.00%

Growth

Metric RGC XERS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 38.37% 5.22%
EPS growth (last fiscal year) (177.78%) 100.86% 42.91%
Revenue growth, 5-year CAGR — 70.20% 7.24%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RGC XERS Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 3.89 0.04
Current ratio 10.77 2.15 2.41
Net debt to EBITDA 1.22 2.67 1.01

Dividend

Metric RGC XERS Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric RGC XERS Drug Manufacturers Specialty & Generic median
Market cap 2.61b 2.38b 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack